Free tool · No signup

Kidney disease treatment & trial finder

Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.

For information only — not medical advice. Always talk to your nephrologist.

Kidney treatment is advancing fast

17 FDA-approved therapies since 2018 8 in the last two years — plus 3 trials enrolling now.

17
Approved therapies
3
Trials enrolling
9
Conditions covered
1
1
5
1
1
6
2
18
19
20
21
22
23
24
25
26

New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.

Common conditions

Treatment Options for Your Diagnosis

2

Foundational care

Start here

Blood-pressure control with ACE inhibitors or ARBs, and SGLT2 inhibitors, are standard first-line therapy for most CKD. Your nephrologist typically starts here.

These are newer and recently approved therapies for Membranoproliferative GN / C3 glomerulopathy — not the full standard of care. Ask your care team whether any fit your situation.

N
Novartis
Iptacopan (Fabhalta)
FDA approved

Oral factor B inhibitor (complement pathway)

APPEAR-C3G

Evidence: 35.1% proteinuria reduction vs placebo; eGFR stabilized and C3 deposits reduced over 12 months.

View the APPEAR-C3G study on ClinicalTrials.gov

Source: FDA prescribing information; APPEAR-C3G, Lancet 2025Verified 2026-07-18

A
Apellis / Sobi
Pegcetacoplan (Empaveli)
FDA approved

Targeted C3 complement inhibitor

VALIANT

Evidence: 68% proteinuria reduction vs placebo at 26 weeks; 71% cleared C3 deposits.

View the VALIANT study on ClinicalTrials.gov

Source: FDA prescribing information; VALIANT, NEJM 2025Verified 2026-07-18

Clinical Trials Related to Your Diagnosis

Actively enrolling studies related to Membranoproliferative GN / C3 glomerulopathy. Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.

No actively enrolling trials we're tracking for Membranoproliferative GN / C3 glomerulopathy right now.

Browse all recruiting Membranoproliferative GN / C3 glomerulopathy trials on ClinicalTrials.gov

For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.

Manage your whole kidney journey

Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.

Get started free